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 Re-engineered viruses or “vectors” are a widely used tool
for nucleic acid delivery, transgene expression, and gene
therapy [1]. Adeno-Associated Virus (AAV) is a commonly
used gene therapy vector [2], with several positive attributes
for gene delivery. Unfortunately the physical size of the AAV
capsid (25 nm) appears to limit the length of the transgene
“payload” to about 4.7 kb, which includes the required in-
verted terminal repeats (143 bp each), the cDNA “cargo,” and
any regulatory elements necessary for cell-specific targeting
and expression [3,4]. AAV serotype 2 (AAV2) is the most com-
monly used vector for gene transfer to the eye. This single
stranded DNA vector typically exhibits a delay (generally 2-3
weeks) in the onset of transgene expression [5] in vivo. This
lag in expression is thought to be due to the time required for
trafficking of the virus to the nucleus, capsid uncoating, and
subsequent stabilization by single- to double-stranded con-
version of the viral genome [6]. For purposes of promoter
optimization, this significantly increases the time required to
fully evaluate regulatory elements and/or the effects of thera-
peutic molecules, particularly in the context of developmen-
tal studies and/or the evaluation of therapeutics for rapidly
progressing diseases. Recently, double-stranded AAV vectors
have been developed [7] that efficiently express their transgene
within days, although the inclusion of the second strand fur-
ther reduces the carrying capacity to <2.5 kb [8].
In contrast, lentiviral (LV) vector capsids have a larger
physical size (about 100 nm) and are capable of packaging
promoter/transgene sequences over twice that of AAV [9]. This
property is invaluable for transfer of large promoter constructs
or transgene coding sequences which cannot be accommo-
dated within AAV vectors [2,10,11]. Furthermore, concentra-
tion and purification of LV vectors may be accomplished by
ultracentrifugation alone, whereas AAV vectors require the use
of column chromatography to generate pure high titer prepa-
rations.
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Functional promoter testing using a modified lentiviral transfer
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Purpose: The importance of retinal glial cells in the maintenance of retinal health and in retinal degenerations has not
been fully explored. Several groups have suggested that secretion of neurotrophic proteins from the retina’s primary glial
cell type, the Müller cell, holds promise for treating retinal degenerations. Tight regulation of transgene expression in
Müller cells is likely to be critical to the efficacy of long-term neuroprotective therapies, due to the genetic heterogeneity
and progressive nature of retinal disease. To this end, we developed a modified lentiviral (LV) transfer vector (pFTMGW)
to accelerate the testing and evaluation of novel transcriptional regulatory elements. This vector facilitates identification
and characterization of regulatory elements in terms of size, cell specificity and ability to control transgene expression
levels.
Methods: A synthetic multiple cloning site (MCS) which can accept up to five directionally cloned DNA regulatory
elements was inserted immediately upstream of an enhanced green fluorescent protein (eGFP) reporter. A cytomegalovi-
rus (CMV) promoter, required for tat-independent viral packaging, is located around 2 kb upstream of the eGFP reporter
and is capable of directing transgene expression. A synthetic transcription blocker (TB) was inserted to insulate the MCS/
eGFP from the CMV promoter. We evaluated eGFP expression from pFTMGW and control constructs using flow cytometry
and quantitative reverse transcriptase polymerase chain reaction (RT-PCR). We also tested and compared the activity and
cell specificity of a computationally identified promoter fragment from the rat vimentin gene (Vim409) in transfection and
lentiviral infection experiments using fluorescence microscopy.
Results: Transfection data, quantitative RT-PCR, and flow cytometry show that around 85% of expression from the CMV
promoter was blocked by the TB element, allowing direct evaluation of expression from the Vim409 candidate promoter
cloned into the MCS. Lentiviruses generated from this construct containing the Vim409 promoter (without the TB ele-
ment) drove robust eGFP expression in Müller cells in vitro and in vivo.
Conclusions: The TB element efficiently prevented eGFP expression by the upstream CMV promoter and the novel MCS
facilitated testing of an evolutionarily conserved regulatory element. Additional sites allow for combinatorial testing of
additional promoter, enhancer, and/or repressor elements in various configurations. This modified LV transfer vector is an
effective tool for expediting functional analysis of gene regulatory elements in Müller glia, and should prove useful for
promoter analyses in other cell types and tissues.
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Neuroscience Institute (HWNI), University of California, Berkeley,
Berkeley, CA 94720-3190; Phone: (510) 642-0178; FAX: (510) 642-
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Another important distinction is that in contrast to AAV,
lentiviruses are enveloped RNA viruses whose genome is re-
verse-transcribed into double-stranded DNA by the viral re-
verse transcriptase soon after entering the target cell. The
double-stranded DNA genome is then readily integrated into
the host genome by the included viral integrase. As a result,
LV vector-mediated transgene expression in non-dividing (and
dividing) cells begins shortly after infection (about 24-48 h),
greatly improving the speed in which experimental promoters
and/or therapies may be evaluated in vivo. Furthermore, their
envelope can be readily modified by insertion of diverse array
of glycoproteins (e.g., xenobiotic or orthologous), allowing
for manipulation of viral tropism and cellular targeting [12].
Developing improved viral vectors possessing precise
regulatory control over transgene expression is a major focus
of gene therapy research. Inclusion of cloned promoter ele-
ments has been the primary approach used to direct and con-
trol transgene expression. However, despite recent advances
in bioinformatics [13-17] and whole genome sequence infor-
mation [18,19], predicting how the DNA sequence and ge-
nomic context combine to control and regulate mRNA expres-
sion remains an inexact science. Currently, there is no reliable
method to predict the manner in which promoter and enhancer
sub-sequences influence and control levels of expression, im-
part positive or negative modulation, or determine cell-type
specific gene expression patterns in mammalian tissues [20].
As additional whole genome sequences become available,
and as computational methodologies continue to improve, the
process for determining which sequences are both functional
and relevant for cell- and context-specific gene expression will
become less empirical. Nevertheless, regulatory elements will
continue to require in vivo evaluation before therapeutic use
in humans can be considered, particularly when expressing
transgenes in diverse multicellular tissues. Until transgenes
can be integrated in a site-specific manner (i.e., to the endog-
enous genomic locus control region), cloned fragments of gene
promoters will continue to be used to direct expression. Though
large promoter elements from individual genes are often suf-
ficient for general laboratory procedures, it is highly desirable
to improve therapeutic control over transgene expression, and
to reduce the size of regulatory elements used in experimental
vectors. Increasing the speed at which small, compound pro-
moters can be evaluated in vitro and in vivo will help to iden-
tify and characterize promoters for use in basic biology and
molecular therapies. Here we detail modifications made to a
LV transfer vector [21] that allows for efficient evaluation and
testing of potentially complex promoter elements. The vector
reduces the need to shuttle promising regulatory elements be-
tween plasmids, permits simultaneous testing of multiple ele-
ments for combinatorial effects on expression of a cDNA pay-
load, and facilitates the identification of smaller promoter el-
ements, enabling a broader use of viruses with more limited
cloning capacities.
METHODS
Creating the pFTMGW plasmid:  A synthetic multiple clon-
ing site (MCS, Figure 1B) containing 11 unique restriction
sites replaced the ubiquitin-C promoter (PacI to BamHI) in
pFUGW (a gift of Dr. David Baltimore, California Institute of
Technology), thereby creating pFMGW. To reduce non-spe-
cific transgene expression driven by the hybrid CMV/LTR, a
154 bp synthetic transcription blocker [22-25] (TB; also see:
pCI-neo vector (Promega, Madison, WI) and pSEAP2 vector
(Clontech Laboratories, Inc., Mountain View, CA)) was PCR
amplified (Forward: 5'-TTC GAA AAT AAA ATA TCT TTA
TTT TCA TTA CAT CTG TGT GTT GGT T-3', BstBI site in
red color; Reverse: 5'-TTA ATT AAA GAG AAA TGT TCT
GGC ACC-3', PacI site in red color) from an existing plasmid
in our laboratory (pAAV-6P1-TB; a gift from Dr. Sebastian
Kügler, University of Göttingen Medical School, Germany
[26]). The TB element was cloned into the PacI site immedi-
ately upstream of the MCS, preserving a PacI site between the
TB and MCS. The resulting plasmid was named pFTMGW
(Figure 1A). The sequence of the pFTMGW plasmid has been
submitted to GenBank, accession number: EF177827.
Cloning the Vim409 promoter fragment:  We cloned a
409 bp fragment (Vim409; rat genome build rn4,
chr17:87846950-87847358; see rat rn4) of the vimentin gene
promoter/5' UTR from Sprague-Dawley (SD) genomic DNA
into the pFTMGW vector. The Vim409 fragment lies immedi-
ately upstream of the vimentin coding sequence (not includ-
ing the bases CATG at the translational start site, red color)
The primers for cloning Vim409 were supplemented with HpaI
(forward, in red color) and BamHI (reverse, in red color) re-
striction sites for directional cloning into pFTMGW: Forward,
5'-GTT AAC CGC GAT CCC TTC TTT CTC AGC AC-3';
Reverse, 5'-GGA TCC GCT TCG AAG GAC GAG GTG
GCC-3'. The sequence was computationally identified using
freely available software at DCODE [27], mandating a mini-
mum of 75% homology between rat and human sequences
over a 250 bp “window.” The resultant Vim409 fragment shares
75.79% (310/409) homology with the human vimentin pro-
moter, including 6 small gaps.
Cell culture:  Rat Müller cells (a gift from Dr. Rong Wen,
University of Pennsylvania) were cultured under standard cul-
ture conditions (37 °C, 5% CO2, 95% air) in DMEM (Cambrex
Corp., East Rutherford, NJ), 10% fetal bovine serum (HyClone,
Logan, UT), 4 mM L-glutamine (Invitrogen Corp., Carlsbad,
CA) and 1X antibiotics (Penicillin (100 U/ml) and Strepto-
mycin (100 µg/ml; Invitrogen)) [28,29]. T24 cells (ATCC
HTB-4) were cultured and propagated similarly to the Müller
cells, except that we used 2 mM L-glutamine, and supple-
mented with 100 nM non-essential amino acids (Invitrogen),
and 1 mM sodium pyruvate (Invitrogen).
Cell transfection and infection:  One sterilized square
cover slip (22 mm number 1, Fisher Scientific, Hampton, NH)
was placed into each well of 6-well plates, and coated with
poly-L-lysine (diluted 1:10 with PBS; Sigma-Aldrich, Mil-
waukee, WI) for 10 min. One day before transfection, rat
Müller or T24 cells were seeded at 0.8-1x106 cells per well in
media without antibiotics. When about 90% confluent, the cells
were transfected with 2 µg of plasmid DNA (see below; Fig-
ure 2) complexed with Lipofectamine 2000 reagent accord-
ing to the manufacturer’s protocol (Invitrogen). For infection
©2007 Molecular VisionMolecular Vision 2007; 13:730-9 <http://www.molvis.org/molvis/v13/a79/>
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with LV, cells were seeded at 1x105 with media (as above),
and 1 µl virus was added the following day.
Twenty-four hours following either transfection or infec-
tion, the culture medium was removed, the cells were rinsed 3
times for 10 min in PBS (pH 7.4), and then fixed with 10%
neutral buffered formalin (Ted Pella, Inc., Redding, CA) at
room temperature for 15 min. Cells were also processed at 48
and 72 h post transfection; no difference was observed be-
tween the samples at different time points (data not shown).
Cells (grown on cover slips) were rinsed 3 times with PBS
and sealed onto microscope slides with Vectashield hard set
mounting medium containing DAPI (Vector Laboratories, Inc.,
Burlingame, CA) using nail polish. Cells were digitally im-
aged on a Zeiss Axiophot fluorescence microscope with an
MRc5 camera (Carl Zeiss, Oberkochen, Germany).
Flow cytometry:  Rat Müller cells grown directly on 6-
well plates were either untreated (No TFX) or transfected with
2 µg pFUGW, pFMGW, pFMGW-CMV, pFTMGW, or
Vim409 (see above; also see Figure 2). All plasmids utilized
eGFP as the reporter molecule, and samples were prepared in
sextuplicate. After 24 h, Müller cells were washed with PBS
and treated with 0.1 ml per well of 0.25% trypsin (Invitrogen).
Culture media was added (0.9 ml) and cells were counted on a
EPICS XL-MCL flow cytometer (Beckman-Coulter, Inc.,
Fullerton, CA), using 488 nm excitation. At least 105 cells
were analyzed, and mean fluorescence intensity (MFI) and
percent eGFP positive cells were calculated for each sample
under identical gating conditions.
Quantitative reverse transcriptase polymerase chain re-
action:  For quantitative RT-PCR analysis, total RNA was iso-
lated 24 h after transfection using RNeasy columns (Qiagen
Corp., Valencia, CA) followed by DNAse I treatment (Sigma;
to eliminate residual DNA). One µg of total RNA was reverse
transcribed (RT) for 2 h at 37 °C for each sample (three per
condition) using random hexamers (Invitrogen) and MMLV-
RT (Promega). One µl (50 ng) was used in each 20 µl PCR
reaction, performed in technical replicate. The primers were
as follows: eGFP forward, 5'-AGC AGC ACG ACT TCT TC-
3'; eGFP reverse, 5'-TCG TCC TTG AAG AAG ATG-3'; Ac-
tin forward, 5'-ACC AAC TGG GAC GAC ATG GAG AA-3';
Actin reverse, 5'-CAT GGC TGG GGT GTT GAA GGT-3'.
We used an eGFP probe (5'-FAM-AGT CCG CCA TGC CCG
AAG GCT-BHQ-3') and a beta-actin probe for internal nor-
malization of each sample (5'-CAL560-CTG GCA CCA CAC
CTT CTA CAA TGA GC-BHQ-3'); both of which were de-
signed (online assays) and ordered from Biosearch Technolo-
gies (Novato, CA). Amplification was performed on an
Mx3000P real-time thermal cycler (Stratagene Corp., La Jolla,
CA). Samples were denatured for 10 min at 95 °C and then
cycled 40 times (30 s at 95 °C, 2 min at 53 °C). We used 300
nM final concentration of primers and probes, 0.1 U per reac-
tion Platinum Taq Polymerase (Invitrogen), and 2.5 mM
MgCl2. Data were analyzed using Stratagene MxPro software
version 3.0, and amplification-based threshold cycle (Ct) val-
ues were exported to Excel (Microsoft Corp., Redmond, WA).
Ct values for eGFP were normalized to beta-actin to control
for variability in amounts of input cDNA, and secondarily
normalized to pFUGW expression levels (100%, Figure 2D).
Lentivirus production:  Lentivirus was packaged by trans-
fecting 293T cells with Lipofectamine 2000 (in IMDM, 10%
FBS, and 2 mM L-glutamine) using a 4-plasmid system con-
sisting of the Vim409 transfer vector, pMDLg/pRRE, pRSV-
REV, and pMD.G (VSV-G [30,31]) as previously described
[32]. Briefly, the cells were plated the previous day in three T-
175 flasks (coated with poly-L-lysine) at a density of 1.5x107
cells/plate. Twelve hours after transfection, media with 1X
antibiotics (Penicillin (100 U/ml) and Streptomycin (100 µg/
ml; Invitrogen)) replaced the media containing the transfec-
tion reagents. Supernatants (containing the viral particles) were
harvested 24 and 48 h after the first media change, and fil-
tered through a 0.45 µm pore PVDF Durapore filter (Millipore
Corp., Billerica, MA). The filtrates were centrifuged in 4 ul-
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Figure 1. Plasmid map of the pFTMGW vector.  A: Two primary
modifications were made to the parent vector, pFUGW; both are sur-
rounded by rectangles. First, a novel multiple cloning site (MCS)
replaced the human ubiquitin-C promoter. Second, a transcription
blocker (TB) was cloned immediately upstream of the MCS to pre-
vent aberrant expression from the upstream CMV promoter. B: The
sequence (5'-3') of restriction enzyme sites included in the new MCS.
ColE1 ori (bacterial origin of replication) and AmpR (ampicillin re-
sistance gene) are used for plasmid replication. The enhanced green
fluorescent protein (eGFP) is the reporter molecule. The CMV (cy-
tomegalovirus promoter), LTRs (long terminal repeats), SD/Psi (splice
donor and viral packaging sequences), CPPT (central polypurine
tract), and WPRE (Woodchuck hepatitis virus post-transcriptional
regulatory element) are virus-related elements.
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tracentrifuge tubes (38.5 ml; number 344058; Beckman-
Coulter) underlaid with 4 ml of sucrose (20%) using a SW-28
rotor spinning at 103,864xg for 2 h at 4 °C. The pellets were
resuspended in 800 µl cold PBS. After 30 min incubation on
ice, the samples were pooled and centrifuged in a SW-41Ti
rotor for 1.5 h at 105,462xg at 4 °C. The pellet was carefully
resuspended in 120 µl cold PBS. After incubation on ice for 2
h the virus was divided into 20 µl aliquots, and used immedi-
ately or stored at -80 °C.
Viral titer determination:  RNA samples from DNAse-
treated Vim409 virus preparations (5.0, 1.0, 0.5, 0.1, and 0.05
µl) were purified using RNeasy columns (Qiagen Corp.,
Valencia, CA). The RNA was reverse transcribed as above,
and 1 µl served as template for qPCR analysis using a dual-
labeled probe to eGFP. The standard curve was determined
using plasmid DNA and the viral titer was calculated to be
about 2x1013 vector genomes (VG) per ml.
For functional titer determination, 293T cells (2x105 cells
per well in a six well plate) were infected with 1.0, 0.5, and
0.25 µl Vim409 virus as described previously [33]. After seven
days DNA from 1x106 cells was isolated using a Puregene
Genomic DNA Purification Kit (Gentra Systems, Minneapo-
lis, MN), and qPCR analysis indicated a titer of about 5x1011
transducing units (TU) per ml.
Subretinal injection:  All animals were treated in compli-
ance with the ARVO (Association for Research in Vision and
Ophthalmology) Statement for the Use of Animals in Oph-
thalmic and Visual Research, and all procedures were in ac-
cordance with protocols approved by the Animal Care and
Use Committee, University of California, Berkeley. Protocols
for subretinal injections have been thoroughly noted by our-
selves and others [32-37]. Briefly, after deep anesthesia, and
after a pilot hole was created at pars plana of the eye, a
Hamilton syringe fitted with a 33-gauge blunt needle contain-
ing 3 µl of virus was inserted into the eye, and the virus was
injected under the retina. The needle was removed slowly, and
the animals recovered on a warming blanket.
Fundus and confocal microscopy:  Prior to sacrifice, eyes
were examined using a RetCam fundus camera (Clarity Medi-
cal Systems, Inc., Pleasanton, CA). Animals were deeply anes-
thetized by intraperitoneal injection with a mixture of xylazine
(13 mg/kg) and ketamine (87 mg/kg). Corneas were directly
anesthetized with drops of proparicane (0.5%), pupils were
dilated with phenylephrine (2.5%) and atropine (1%) drops,
and fluorescent in vivo fundus images were collected. Ani-
mals were euthanized by CO2 overdose followed by cervical
dislocation, and eyes were enucleated and fixed in 10% neu-
tral buffered formalin (Ted Pella). The cornea and lens were
removed and the posterior pole was returned to fixative for 2
h, rotating at 4 °C. After PBS rinses (3x10 min), the eyecup
was embedded in Tissue Freezing Medium (TBS, Durham,
NC). Eyes were cryosectioned at 30 µm, and sections were
collected on ProbeOn Plus microscope slides (Fisher Scien-
tific). Sections were mounted under cover slips with
Vectashield mounting medium containing DAPI (Vector Labo-
ratories). eGFP positive retinal sections were analyzed on an
Axioplan 510 Meta confocal microscope (Carl Zeiss).
RESULTS
Quantitative analysis:  We generated a lentiviral vector back-
bone that incorporated a large MCS in place of the ubiquitin-
C promoter (pFMGW). By replacing the cloned ubiquitin-C
promoter with the MCS, we anticipated a complete loss of
eGFP expression in transfection experiments. However, us-
ing both flow cytometry (Figure 2A) and quantitative RT-PCR
(Figure 2B), we observed that pFMGW continued to express
high levels of eGFP in cultured cells (Figure 2A,B). Compar-
ing pFUGW with pFMGW, flow cytometry analysis indicated
little change in eGFP protein expression (Figure 2A), and quan-
titative RT-PCR indicated a modest (about 20%) decrease in
mRNA transcript levels (Figure 2B). These results suggested
that the upstream CMV promoter was strongly influencing
eGFP gene expression. Excising the CMV promoter sequence
(pFMGW-CMV) dramatically reduced eGFP expression (Fig-
ure 2A,B), indicating that despite a distance of >2 kb upstream,
the external CMV promoter was capable of directing high lev-
els of eGFP transgene expression.
As an alternative to removing the CMV/LTR from the
backbone vector, a sequence that is necessary for producing
high titer viruses in the packaging cell line, we tested the ef-
fectiveness of a synthetic TB element inserted immediately
upstream of the MCS (Figure 1). The TB element has been
previously characterized as containing a synthetic poly-A
(SPA) sequence (AATAAA sequence and a GT/T-rich sequence
with the correct spacing of 22-23 nucleotides between them)
[22], and a C2 transcriptional pause site [23], which slows the
processivity of the RNA polymerase complex. Quantitative
assessment of TB function by both flow cytometry (Figure
2A) and quantitative RT-PCR (Figure 2B) indicated a reduc-
tion in eGFP expression by approximately 85%. A second TB
element arranged in tandem did not enhance the blocking ef-
fect (data not shown). Moreover, the mean fluorescence in-
tensity (MFI) in the flow cytometry samples (Figure 2) indi-
cated a reduction in the amount of eGFP protein produced in
the small population of transfected cells that circumvented the
transcriptional block. Cells transfected with pFMGW had a
MFI of 34.32, while inclusion of the TB element in pFTMGW
reduced the MFI to 8.3.
To validate the suitability of our modified pFTMGW vec-
tor for promoter screening in vitro, we measured eGFP ex-
pression from a proximal promoter fragment of a glial spe-
cific gene cloned into the MCS of pFTMGW. Using compara-
tive genome analysis tools at DCODE [27], we selected and
PCR-cloned a promoter fragment (Vim409) from the rat
vimentin gene. Transfecting the Vim409 construct resulted in
robust eGFP expression in cultured Müller cells. By flow
cytometry analysis (Figure 2A), the Vim409 plasmid drove
eGFP expression as well as the ubiquitin-C promoter in the
parent vector (pFUGW). Similarly, by quantitative RT-PCR
analysis, transfection with the Vim409 promoter resulted in
equal or slightly higher levels of expression when compared
to pFUGW (Figure 2B). These data suggest that the pFTMGW
vector is useful for assessing gene expression from promoter
sequence(s) cloned into the MCS, without significant “non-
specific” expression from upstream cis-acting elements.
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Qualitative analysis:  Microscopic evaluation of Müller
cells transfected with pFTMGW (Figure 3A) also demonstrated
significantly reduced numbers of eGFP positive cells when
compared with pFUGW (Figure 3B). Though this was an im-
portant improvement for transfection studies, one of our pri-
mary goals was to create a vector that can be used to quickly
screen promoters in vivo as well as in vitro. To generate high
titer viral vectors, the TB was removed before packaging. To
accomplish this we engineered BstBI and PacI sites to flank
the TB, allowing for efficient removal, filling-in, re-ligation,
and transformation: all of which can be completed in less than
a day. We removed the TB from the Vim409 construct and
generated infectious Vim409 LV particles (see methods). The
Vim409 virus infected and expressed eGFP in Müller cells,
both in vitro (Figure 3C) and in vivo (Figure 3D,E). Cultured
Müller cells expressed eGFP within 24 h of infection with 1
µl of the Vim409 LV vector (Figure 3C). Similarly, 5 days
after a 3 µl subretinal injection of Vim409 LV vector into rat
eyes, eGFP expression was apparent in vivo in a fluorescent
fundus photograph (Figure 3D). In retinas examined by con-
ventional fluorescence and confocal microscopy, eGFP expres-
sion was apparent in the radial Müller glia and in some pre-
sumed astrocytes, cell types that normally express vimentin
(Figure 3E).
The promoter specificity of the Vim409 construct was vali-
dated by transfecting Müller and T24 cells with several plas-
mid constructs (2 are shown; Figure 4). T24 cells are known
to lack vimentin [38] and therefore serve to control for non-
specific expression by sequences outside of the MCS-cloned
Vim409 promoter. In Figure 4 we show Müller cells (Figure
4A,B) and T24 cells (Figure 4C,D) transfected with Vim409
(Figure 4A,C) and Vim409-CMV (Figure 4B,D). We found
that both constructs drove high levels of eGFP expression in
vimentin-positive Müller cells with no appreciable difference.
These data indicate that Vim409 directs transgene expression
in Müller cells as expected, irrespective of the upstream CMV
promoter “leaking” through the TB element. In direct con-
trast, in T24 cells, the Vim409-CMV construct (Figure 4D)
fails to drive eGFP expression, while the Vim409 construct
continues to show some CMV-driven expression (Figure 4C).
These data suggest that the Vim409 promoter is specific for
vimentin expressing cells, and that gene-specific promoters
can be effectively evaluated using the pFTMGW plasmid back-
bone vector.
DISCUSSION
 We have developed a vector for rapidly assessing the effec-
tiveness of individual or compound promoter elements to di-
rect gene expression in vitro and in vivo. In the current paper
we describe modifications made to a LV transfer vector, and
how the modified vector can be used to test cloned promoter
elements; in this case, we evaluated the ability of a
computationally defined fragment of the vimentin promoter
to drive eGFP expression in retinal Müller cells. Recently, we
demonstrated that LV vectors containing “full length”
vimentin, GFAP, and CD44 promoters can efficiently infect
and direct robust eGFP expression in Müller glia [33]. Fur-
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Figure 2. Quantitative analysis of eGFP expression in transfected
cells.  A: Flow cytometry analysis of eGFP expressing Müller cells.
Nearly confluent cells in 6-well plates were un-transfected (No TFX),
transfected with 2 µg of control vectors (pFUGW, pFMGW, pFMGW-
CMV, pFTMGW), or transfected with 2 µg of a 409 bp fragment of
the rat vimentin promoter cloned into pFTMGW (Vim409). Greater
than 105 cells were analyzed in each of six replicate samples for each
condition. Gating was set such that positive cell counts in the No
TFX samples were less than 0.07% of all cells. B: Quantitative RT-
PCR analysis of eGFP expression. Total RNA was isolated from cul-
tured Müller cells transfected with the same set of plasmids as in A,
and reverse transcribed. eGFP and β-actin transcript expression were
measured using Taqman fluorescent probes. Threshold cycle num-
bers were first internally normalized (within each individual reac-
tion) to β-actin, and secondarily normalized to pFUGW eGFP ex-
pression levels (set to 100%). Samples were analyzed in triplicate.
pFUGW is the parent plasmid. pFMGW is pFUGW with the MCS in
place of the ubiquitin-C promoter. pFMGW-CMV is the pFMGW
plasmid lacking the CMV promoter. pFTMGW is pFMGW with the
TB cloned immediately upstream of the MCS. Vim409 is the 409 bp
fragment of the rat vimentin promoter/5' UTR cloned into pFTMGW.
Error bars represent 1 SD for panels A and B.
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Figure 3. Microscopic evalua-
tion of eGFP expression in
Müller cells.  A: Müller cells
transfected with 2 µg of the
modified LV transfer vector
(pFTMGW) for 24 h. B:
Müller cells transfected with 2
µg of the parent pFUGW plas-
mid for 24 h. Note the reduc-
tion in eGFP expression when
the TB and MCS elements are
introduced. C: Cultured Müller
cells infected with the Vim409
virus expressing eGFP. D: An
adolescent SD rat injected
subretinally with 3 µl of the
Vim409 virus. Shown here is
an in vivo fluorescent fundus
photograph of an eye, 5 days
after injection. Arrows denote
the area of viral infection and
consequent eGFP expression.
E: The eye shown in D was re-
moved and processed for con-
focal microscopy. Shown here
is a confocal image of a retinal
cross-section, 5 days following
infection with the Vim409 vi-
rus. The arrow indicates eGFP
expression in Müller cell bod-
ies, and large arrowheads iden-
tify the characteristic Müller
cell processes that span the
thickness of the neural retina.
The small arrowheads indicate
astrocytes in the ganglion cell
layer (GCL), the other pre-
dominant glial cell type in the
retina, which also express
vimentin. SRS, subretinal
space; ONL represents outer
nuclear layer; INL represents
inner nuclear layer. Scale bars
in A, B, C, and E represent 100
µm.
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thermore, numerous investigators have studied the ability of
lentivirus, pseudotyped with diverse envelope glycoproteins
and containing various promoters, to infect mammalian reti-
nas [32-36]. These data suggest that the expression of pack-
aged transgenes depends on the combination of pseudotype
and promoter elements. Infection of RPE, photoreceptors, and
inner retinal cells (including Müller cells) has been demon-
strated under such conditions. Several investigators have sug-
gested that Müller glia may be utilized as a cellular conduit
for delivering neuroprotective agents and treating retinal dis-
ease [39-43]. A necessary concern of any viral-based therapy
is how to properly regulate expression of the delivered
transgene(s). This vector will enhance our ability to accurately
examine unique combinations of regulatory elements and how
they influence transgene expression. We are using this vector
to better characterize promoters for controlling the expression
of transgenes in the context of lentiviral gene therapy. Impor-
tantly, however, the vector described here should facilitate
promoter analysis in a variety of experimental and therapeu-
tic applications.
The pFUGW plasmid was originally modified [37] by re-
moval of the viral enhancer and promoter elements, and addi-
tion of a hybrid 5' LTR generated by replacing the LTR U3
sequence with a CMV promoter. These modifications allow
for Tat-independent transcription with no measurable effect
on viral titers, and eliminate the cis-acting promoter influence
in vivo. The original vector was also designed to be self-inac-
tivating, by deleting 133 bp of the U3 region of the 3' LTR, to
prevent mobilization of the virus after integration into host
cells [37]. We further modified the pFUGW LV transfer vec-
tor [21] to expedite the discovery and characterization of
shorter regulatory elements capable of directing gene expres-
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Figure 4. Failure of Vim409 to drive eGFP expression in cells that lack endogenous vimentin expression.  A: Müller cells transfected with 2 µg
of the Vim409 plasmid construct for 24 h. The construct included the upstream hybrid CMV/LTR and the TB element. B: Müller cells
transfected with 2 µg of the Vim409 plasmid after removing the CMV/LTR. Expression of eGFP was indistinguishable between A and B. C:
Cultured T24 cells transfected with 2 µg of the Vim409 plasmid construct for 24 h. D: Cultured T24 cells transfected with 2 µg of the Vim409
plasmid after removing the CMV/LTR. Note the near complete loss of expression when the CMV/LTR is removed, validating the specificity
of the Vim409 promoter for directing expression in vimentin-positive cells, and indicating that expression in C is due to the CMV/LTR
promoter driving expression through the TB in a subset of cells. Scale bar in A represents 100 µm.
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sion in retinal glia. First, we wanted to equip the plasmid with
an ample multiple cloning site upstream of eGFP. The MCS
enables the ability to test unique combinations of DNA se-
quences for their ability to regulate transgene expression. For
example, up to 5 sub-sequences from the same promoter can
be tandemly cloned, arranged, and tested. In this manner, re-
peated elements or sequences not predicted to be substrates
for transcription factor binding/regulation could be eliminated
from testing and analysis, if desired. Moreover, hybrid pro-
moters could be designed to include sequences from regula-
tory regions of different genes. The hope is that hybrid (poly-
genic) promoters may exhibit unique regulatory characteris-
tics that can be exploited for improving our understanding of
gene expression, and possibly for use as regulatory elements
in experimental therapies. The resulting vector (pFTMGW)
has broad applicability in both in vitro and in vivo assays, and
reduces the time and effort required for shuttling, sequencing,
screening, and subcloning DNA regulatory elements into dif-
ferent plasmid constructs. The pFTMGW vector can be used
to rapidly and efficiently test the functional activity of cloned
regulatory elements in both transfection- and infection-based
assays. This vector should facilitate the discovery of regula-
tory elements for retinal gene expression, and will likely be
useful for studying promoter/enhancer activity in the brain and
other tissues.
We found that the CMV promoter (located over 2 kb up-
stream of the eGFP) was capable of driving high levels of
“non-specific” transgene expression. We felt it was important
to prevent undesirable eGFP expression by the external CMV
promoter in the plasmid backbone, which is required for Tat-
independent virus production [37] in vitro. We tested and de-
termined that a TB element is effective at mitigating the ma-
jority (about 85%) of transgene expression from the CMV pro-
moter (Figure 2). Using the Vim409 promoter, we observed
that an MCS-cloned promoter directs reporter gene expres-
sion in transfected cells at significantly higher levels than con-
trol constructs (e.g., pFTMGW). However, it should be noted
that because about 15% of gene expression leaks through the
TB (in Müller cells), likely due to the robustness of the CMV
promoter, it may be worthwhile to excise the CMV/LTR from
experimental constructs before in vitro testing. This may be
particularly true if the sequence of interest is expected to di-
rect low levels of gene expression or when quantitative mea-
surements are required. It is our experience, nonetheless, that
active promoters are readily identified (over and above the
CMV-driven expression) during microscopic screening of
transfected experimental promoter constructs.
A consideration in the design of the pFTMGW vector was
facilitating efficient removal of the TB element to allow tran-
scription of the packaged viral genome (between the two
LTRs). TB removal is necessary because the packaged
lentiviral RNA genome is produced by Pol II-mediated tran-
scription from the hybrid CMV/LTR [37]. Preventing tran-
scription of the full-length genome by prematurely stopping
transcription (by the TB) would block generation of whole
RNA transcripts required for packaging into capsids. A re-
striction digestion reaction to remove the TB element followed
by ligation and subsequent plasmid isolation is all that is re-
quired for any pFTMGW-based plasmid to become viable for
generating infectious LV particles. To validate the ability of
these constructs to be used for virus production and subse-
quent infection assays (Figure 3), we packaged active LV us-
ing the Vim409 plasmid after removal of the TB by BstBI and
PacI restriction endonuclease digestion (see Figure 1). As
shown in Figure 3, the Vim409 virus efficiently infected and
expressed eGFP in vimentin-positive cells. Circumventing the
need to re-clone fragments into different plasmid backbones
should expedite the functional evaluation of experimental pro-
moters.
A common issue in molecular cloning is the presence of a
“required” restriction site within a desired DNA fragment;
generally precluding a simple cloning procedure, and often
necessitating multiple workaround steps. Having 11 unique
restriction sites in the MCS (Figure 1B) assures that virtually
any small (<1000 bp) DNA fragment can be directionally
cloned into at least one pair of sites with relative ease. Fur-
thermore, having numerous sites also allows for tandem, in-
verted, and combinatorial cloning of regulatory elements into
a single “promoter construct,” and thus offers the potential to
analyze more complex promoter designs.
We demonstrate that a modified LV vector backbone plas-
mid can be useful for expediting the identification of func-
tional promoter elements. Because LV vector-mediated gene
expression is rapid, and tropism can be manipulated by chang-
ing the envelope protein expressed in the cell line used for
viral packaging [12], we believe that it can be effectively uti-
lized to identify functional, cell-specific promoters in diverse
experimental paradigms. We show here that a single vector,
pFTMGW, can be used for transfection, flow cytometry, quan-
titative RT-PCR, and viral infection experiments. Use of this
vector should increase throughput and discovery of regula-
tory elements needed to drive gene expression in a variety of
cell types and experimental systems.
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